ECCMID
Molecular TB Assay From PBD Biotech Shows Promise in Detecting Latent-to-Active Disease Risk
Premium
The blood-based assay, called Actiphage, combines phage-induced lysis of infectious bacteria and molecular detection of bacterial DNA.
The prototype assay, presented at ECCMID in Lisbon, integrates sample preparation and RT-PCR to measure a six-mRNA host signature.
The method, presented at the European Congress of Clinical Microbiology and Infectious Diseases, may provide results in hours rather than a week or more.
An early user of a new Mycoplasma genitalium and antibiotic resistance test from SpeeDx that uses the Xpert cartridge shared some initial validation data.
The company cites flexibility and ease of use as its main selling points, and is partnering with IVD firms like Randox and R-Biopharm on assay development.